Resources for Researchers

NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.

23 Results

The ARLG biorepositories were created to aid in the development and evaluation of novel diagnostic tests and laboratory techniques, study mechanisms of resistance, generate preliminary data for study concepts, and support/mentor early-stage investigators pursuing research in the field of antibacterial resistance.

The BEI Resources Repository is a central repository that supplies organisms and reagents to the broad community of microbiology and infectious diseases researchers. Materials are available through an online catalog.

The NIAID-funded Bioinformatics Resource Centers provide data-driven, production-level, sustainable computational platforms to enable sharing and access to data, portable computational tools, and standards that support interoperability for the infectious diseases research community. 

NIAID CEIRS provides the BEI Resources Repository with high-priority reagents from the CEIRS community. Reagents include plasmids, antibodies, proteins, and virus isolates. Reagents not available through BEI can be requested on this page. Non-BEI reagents may be available from CEIRS researchers upon request.

The Centers for Research on Structural Biology of Infectious Diseases (CRSTAL-ID) provide the research community with: 3-D protein structures and protein-ligand complexes; Sequence-verified clones and peptides; Services that deliver requested 3-D structure determination; and Molecular screening of proteins in complex with inhibitors, cofactors and substrate analogs

The Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB) is a NIAID-led partnership with RTI International, which oversees the design, synthesis, and management of external investigator-submitted libraries of chemical compounds specifically targeting Gram-negative bacteria.

NIAID’s Diagnostics Development Services program offers reagents, platform testing, and planning and design support to accelerate product development of in vitro diagnostics (IVD) for infectious diseases, from research feasibility through clinical validation.

The Early Phase Clinical Trial Units (EPCTUs) support the design, development, implementation, and conduct of Phase 0 to Phase 2 clinical trials, including proof-of-concept studies in healthy, special, and disease-specific populations, carried out in an expeditious and efficient manner, aided by bioanalysis when necessary, against viral, bacterial, parasitic, and fungal pathogens and

The Filariasis Research Reagent Resource Center (FR3) maintains oversight of filarial parasites, SOPs, and molecular reagents. FR3 is comprised of two divisions: The Parasite Resource Division and the Molecular Resources Division.

The GCID use and develop or improve innovative applications of genomic technologies, such as RNA sequencing and metagenomics, and provide rapid and cost-efficient production of high-quality genome sequences of microorganisms, invertebrate vectors of infectious diseases, and hosts and host microbiomes. Multiple strains and isolates of specific microbial species, populations and communities have been and continue to be sequenced.

The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical specimens.

The National Biocontainment Laboratories (NBLs) and Regional Biocontainment Laboratories (RBLs) provide BSL4/3/2 and BSL3/2 biocontainment facilities, respectively, for research on biodefense and emerging infectious disease agents.  

This contract program supports the development and refinement of animal models and animal replacement technologies and provides in vivo preclinical testing services, ranging from screening and proof-of-concept to GLP efficacy studies.

The Schistosomiasis Resource Center (SRC) provides three major strains of snails (Biomphalaria glabrata, Bulinus truncatus, and Oncomelania hupensis) and rodents infected with S. haematobium, S.

NIAID-funded researchers at ATCC and Tufts University have developed SOPs for creating continuous in vitro culture systems for the intestinal parasite Cryptosporidium.

The Systems Biology Consortium for Infectious Diseases is a community of systems biologists who integrate experimental biology, computational tools and modeling across temporal and spatial scales to improve our understanding of infectious diseases.

The Therapeutic Development Services program offers a collection of preclinical services to support the development of products intended for use in the cure, mitigation, diagnosis, or treatment of disease caused by a pathogen or certain toxins.

Provides services to facilitate preclinical development of materials that are derived from biotechnology processes. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

Therapeutic Development Services - Interventional Agents program provides services to facilitate preclinical development of therapeutics and new in vivo diagnostics for infectious pathogens, including bacteria, viruses, parasites, fungi, and toxins. Services will be conducted at the appropriate regulatory compliance level dependent on the stage of product development.

The Vaccine and Treatment Evaluation Units (VTEUs), supported by the Division of Microbiology and Infectious Diseases (DMID) since the 1960s, comprise a consortium of contracts with academic centers and organizations that provides a ready resource for the conduct of clinical trials to evaluate promising vaccines, treatments, and diagnostics for infectious diseases.

 

The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).

The WRCEVA program maintains the Emerging Viruses and Arboviruses Reference Collection and provides reagents and support for investigations of virus outbreaks throughout the world. Information about WRCEVA can be found at https://www.utmb.edu/wrceva/home.

This resource provides Good Manufacturing Practice (GMP)-quality candidate vaccine viruses for zoonotic influenza, a critical component of global influenza pandemic preparedness. Candidate vaccine viruses have been used to create H5, H9, and H7 vaccine lots that have been deployed to national stockpiles and/or clinical trials.